Pain Therapeutics Announces Encouraging Clinical Data With a New Drug for Skin Cancer
SAN MATEO, Calif., March 23, 2010 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today announced encouraging clinical data with PTI-188, an early-stage drug for metastatic melanoma. Metastatic melanoma is a lethal form of skin cancer in which patients typically have a median survival time of 9 months.